Background Omalizumab (Xolair®; Novartis) is a recombinant IgG1 monoclonal antibody that selectively binds to human IgE and is approved for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps. Since its approval, the use of Omalizumab has been investigated in clinical studies for food allergies, atopic dermatitis, and eosinophilic gastritis. However, no approval exists for these indications. Allergen immunotherapy (AIT) is the only causal therapy used for allergic rhinitis (AR) and asthma. Systemic side effects are rare but can limit therapy.
No takes yet. Share an insight, caveat, or question.
Krokenberger et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: